Approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by ...
Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib), an oral, selective MEK inhibitor, has been approved in Canada for the treatment of adult patients with neurofibromatosis type 1 (NF1) who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results